1 Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. A Achhra, J Amin, MG Law, S Emery, J Gerstoft, FM Gordin, MJ Vjecha, JD Neaton, DA Cooper for INSIGHT ESPRIT & SILCAAT study groups.
AIDS 2010; 24(12):1877-1886. abstract
2 Interleukin-2 Therapy in Patients with HIV Infection. The INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee.
N Engl J Med 2009; 361:1548-1559. abstract
3 Determination of the underlying cause of death in three multicenter international HIV clinical trials. AR Lifson and the INSIGHT Cause of Death Writing Group: WH Belloso, C Carey, RT Davey, D Duprez, WM El-Sadr, JM Gatell, DC Gey, JF Hoy, EA Krum, R Nelson, DE Nixon, N Paton, C Pedersen, G Perez, RW Price, RJ Prineas, FS Rhame, J Sampson, J Worley.
HIV Clin Trials 2008; 9:177-185. abstract
4 Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. A Lifson, FS Rahme, WH Belloso, UB Dragsted, WM El-Sadr, JM Gatell, JF Hoy, EA Krum, R Nelson, C Pedersen, SL Pett, RT Davey for the ESPRIT and SILCAAT Research Groups.
HIV Clin Trials. 2006;7(3):125-141 abstract